Topline data from a one-year interim analysis of the ongoing phase 2 trial show that 11 out of 16 patients had objective clinical responses, equaling a 69% Overall Response Rate 15 out of the 16 patie ...

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress ...

A Kildare-based GP has appeared before a fitness to practise committee over allegations that he made comments disapproving of the use of Covid-19 vaccines and displayed anti-vaccine posters in his ...

A Kildare-based GP has appeared before a fitness-to-practice inquiry over allegations that he made comments disapproving of the use of Covid-19 vaccines and displayed anti-vaccine posters in his ...

Because viruses evolve as they infect people, the CDC has recommended updated covid vaccines each year. Last fall’s booster was designed to target the omicron variant circulating in 2023. This year, ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European ...

(Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the European Society for Molecular Oncology (“ESMO”) ...

Now, new research from the drug company Moderna suggests its new mpox vaccine, based on mRNA technology, might do a better job at shielding recipients from harm. The findings were published Sept.